Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Bifeprunox

From Wikipedia, the free encyclopedia
Experimental dopamine D2 receptor partial agonist researched as an antipsychotic agent
Pharmaceutical compound
Bifeprunox
Clinical data
ATC code
  • none
Identifiers
  • 7-[4-(biphenyl-3-ylmethyl)piperazin-1-yl]-1,3-benzoxazol-2(3H)-one
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC24H23N3O2
Molar mass385.467 g·mol−1
3D model (JSmol)
  • O=C2Oc1c(cccc1N2)N5CCN(Cc4cccc(c3ccccc3)c4)CC5
  • InChI=1S/C24H23N3O2/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19/h1-11,16H,12-15,17H2,(H,25,28) checkY
  • Key:CYGODHVAJQTCBG-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Bifeprunox (INN; code nameDU-127,090) is anatypical antipsychotic which, similarly toaripiprazole, combines minimalD2 receptoragonism withserotonin receptor agonism.[1] It was under development for the treatment ofschizophrenia, psychosis and Parkinson's disease.[2]

In a multi-center, placebo-controlled study, 20 mg of bifeprunox was found to be significantly more effective than placebo at reducing symptoms of schizophrenia, with a low incidence of side effects.[3] An NDA for Bifeprunox was filed with theU.S. Food and Drug Administration in January 2007. The FDA rejected the application in August 2007.[4] In June 2009, Solvay and Wyeth decided to cease development because "efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia."[5]

Pharmacodynamics

[edit]

Bifeprunox is an atypical antipsychotic that is a partial D2 agonist.

See also

[edit]

References

[edit]
  1. ^Cuisiat S, Bourdiol N, Lacharme V, Newman-Tancredi A, Colpaert F, Vacher B (2007). "Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities".J. Med. Chem.50 (4):865–76.doi:10.1021/jm061180b.PMID 17300168.
  2. ^"Bifeprunox".go.drugbank.com. Retrieved2023-11-16.
  3. ^Casey DE, Sands EE, Heisterberg J, Yang HM (October 2008). "Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study".Psychopharmacology.200 (3):317–31.doi:10.1007/s00213-008-1207-7.PMID 18597078.S2CID 23291727.
  4. ^Wyeth and Solvay say FDA rejects application for antipsychotic drug bifeprunox. Thomson Financial, August 10, 2007.
  5. ^Pipeline update - following an interim analysis the studies with bifeprunox for the treatment of schizophrenia is discontinuedArchived 2011-07-14 at theWayback Machine Lundbeck Press Release.
Typical
Disputed
Atypical
Others
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Phenylpiperazines
Benzylpiperazines
Naphthylpiperazines
Quinolinylpiperazines
Diphenylalkylpiperazines
Pyrimidinylpiperazines
Pyridinylpiperazines
Benzo(iso)thiazolylpiperazines
Tricyclic-linked piperazines
Others/uncategorized
Retrieved from "https://en.wikipedia.org/w/index.php?title=Bifeprunox&oldid=1285944327"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp